Navigation Links
BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007


BIRMINGHAM, Ala., Nov. 6 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its third quarter 2007 financial results will be released on Thursday, November 8, 2007. At 10:00 a.m. Eastern Time, BioCryst will host a conference call and live webcast. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, and Stuart Grant, Senior Vice President and Chief Financial Officer. BioCryst management will discuss the Company's third quarter results and provide an update on the Company's programs and business results.

To access the webcast via the internet, log on to Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternately, please call 1-800-860-2442 (U.S.) or 1-412-858-4600 (international). Telephone replay will be available. To access the replay, please call 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and dial the participant passcode 413134#. The webcast will be archived on

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including forodesine HCl in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that final results and analysis of the peramivir Phase II trial may differ from the preliminary results and analysis, that DHHS and the FDA may not agree with our analysis, that DHHS may further condition, reduce or eliminate future funding of the peramivir program, that we may not commence in timely fashion or at all the planned Phase III trial for peramivir and if commenced, it may not be successful, that the pivotal trial with forodesine HCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of forodesine HCl, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trials for forodesine HCl that are currently planned to be pivotal, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.


BioCryst Pharmaceuticals, Inc.

Jonathan M. Nugent

V.P. Corporate Communications

(205) 444-4633

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
2. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
3. First New York/New Jersey Health Care Report Card Released
4. Cleveland Clinic Press Releases Journal-Writing Book Write for Life: Healing Body, Mind, and Spirit Through Journal Writing by Sheppard B. Kominars, Ph.D.
5. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
6. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
7. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
8. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
9. Verdict One Releases Directory of Board Certified Attorneys for Consumers
10. Academy releases emergency preparedness tools to enable millions more people to shelter in place
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Rodney E. Willey , has answered a ... Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea through ... a Koala Center for Sleep Disorders in the US, one of four in the Illinois ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Autism Speaks, ... the global movement driven by social media and the generosity of people around the ... encourage their social media networks to give – and share the personal stories behind ...
(Date:11/24/2015)... Tennessee (PRWEB) , ... November 24, 2015 , ... ... Pharmacy Quality Trend Report . Throughout the past year there have been multiple breakthroughs ... mature state. During this transition, PharmMD has enabled their customers and partners to stay ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... “I am so thrilled, as a newbie ... after learning she had won a $7,500 School Lounge Makeover® from California Casualty . ... most of the staff has a much longer tenure. , “This is such an amazing ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
(Date:11/24/2015)... BERN, Switzerland , November 24, 2015 ... for Biomedical Engineering Research of the University of ... Endocrinology, Diabetes and Clinical Nutrition of the Bern University ... an exclusive collaboration to develop a novel generation artificial ... personalised delivery of insulin for diabetic patients with the ...
(Date:11/24/2015)... 2015 st  Scientific Assembly and Annual Meeting ... (RSNA) taking place in Chicago on Nov-29 ... --> st  Scientific Assembly and Annual Meeting of the ... place in Chicago on Nov-29 th ... Molecular Dynamics will present its revolutionary whole body CZT digital ...
Breaking Medicine Technology: